Lake Street analyst Frank Takkinen reiterated a Buy rating on Biolase (BIOL – Research Report) today and set a price target of $1.50. The company’s shares opened today at $0.35.
Takkinen covers the Healthcare sector, focusing on stocks such as Biolase, TELA Bio, and NeuroPace. According to TipRanks, Takkinen has an average return of -13.4% and a 28.57% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biolase with a $1.25 average price target, implying a 257.14% upside from current levels. In a report released today, Maxim Group also maintained a Buy rating on the stock with a $1.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
BIOL market cap is currently $9.03M and has a P/E ratio of -0.11.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BIOLASE, Inc. is a medical device company, which engages in the development, manufacture, market and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.
Read More on BIOL:
